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Ultrasound-targeted microbubble destruction (UTMD) is a promising technique for non-invasive, targeted drug
delivery, and its applications in chemotherapeutic drug delivery to solid tumors have attracted growing interest.
Ultrasound, which has been conventionally used for diagnostic imaging, has evolved as a promising tool for
therapeutic applications mainly because of its ability to be focused deep inside the human body, providing a
modality for targeted delivery. Although originally being introduced into clinics as ultrasound contrast agents,
microbubbles (MBs) have been developed as a diagnostic and therapeutic agent that can both be tracked through
non-invasive imaging and deliver therapeutic agents selectively at ultrasound-targeted locations. Whereas free
drugs often possess harmful side effects, their encapsulation in MBs and subsequent local release at the targeted
tissue by ultrasound triggering may help improve the margin of safety. In the past 10 years, the feasibility and
safety of UTMD have been extensively tested using normal animal models. Most recently, a growing number of
preclinical studies have been reported on the therapeutic benefits of UTMD in the delivery of chemotherapeutic
drugs to various malignant tumors, such as brain, liver, eyelid, pancreas, and breast tumors. Increased drug
concentration in tumors and reduced tumor sizes were achieved in those tumors treated with UTMD in
combination with chemotherapeutic drugs, when compared to tumors treated with chemotherapy drugs alone.
This review presents an overview of current preclinical applications of UTMD in chemotherapeutic drug delivery for
the treatment of cancers along with a discussion of its future developments.
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Cancer is a leading cause of death worldwide. Systemic
chemotherapy is the main treatment available for a wide
variety of cancers; however, the lack of tumor response
to chemotherapy is well documented in many cancer
types [1]. The main hindrance for the distribution of an-
ticancer agents to the tumor site is the poorly organized
tumor vasculature, irregular blood flow, and high inter-
stitial pressure within the tumor tissue [2-4]. This insuf-
ficient response of cancer to chemotherapeutic drugs
have urged the need for developing new strategies for
enhancing localized drug delivery to tumors while mi-
nimizing systemic side effects. Ultrasound (US) in combi-
nation with microbubbles (MBs) has been demonstrated
as a new promising strategy for targeted drug delivery to* Correspondence: jooha@medicine.washington.edu
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distribution, and reproduction in any mediumtumors [5,6]. US is the most widely used diagnostic me-
dical imaging modality, and its potential in therapeutics
has been explored for several decades [7,8]. It is non-
invasive, has no hazardous ionizing radiation, and can
transmit energy deep into the human body. Moreover,
the ultrasound beam can be focused to a small focal re-
gion (usually in the order of millimeters) deep into tis-
sues, which allows highly precise targeting of diseased
tissues during therapy. This relatively safe and non-
invasive transmission of energy deep into the body is the
key to ultrasound-mediated drug delivery [9].
MBs, bubbles with diameters of less than 10 μm, are
made of a phospholipid, surfactant, albumin, or synthetic
polymer shell filled with high molecular weight gas with
a very low water solubility (e.g., sulfurhexafluoride or
perfluorepropane gas) [10]. Bioactive substances (e.g.,
genes, drugs, proteins, and gene silencing constructs)
can be attached to or incorporated in the MBs. Althoughntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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agents for enhancing the ultrasound signals from the
blood pool, MBs have been developed as an agent with
both diagnostic and therapeutic capabilities.
The technique that uses low-intensity US in combin-
ation with MBs is often called US-targeted MB destruc-
tion (UTMD) [11-13]. Compared to conventional systemic
delivery of chemotherapy drugs, drug delivery by UTMD
is a targeted delivery strategy. Targeted drug release can
be achieved when an external US beam is focused within a
tumor, so only MBs passing through the beam interact
with the US energy. While many externally triggered drug
release techniques have been explored, UTMD is unique,
in that it can facilitate the drug to overcome the tumor
barriers to reach tumor cells. When MBs are exposed to
an US field, the US mechanical wave causes them to cavi-
tate, which is a broad term for US-induced activities of
bubbles, including their formation, oscillation, and col-
lapse. The interaction of the US-activated MBs with tissue
results in thermal and mechanical effects. For drug deliv-
ery applications, the US parameters were selected to in-
duce mechanical effects while reducing the chance of
generating heat as it can lead to thermal ablation of the
tumor [14,15]. These mechanical effects have the potential
to increase microvessel permeability of drugs, enhance
drug penetration through the interstitial space, and in-
crease tumor cell uptake of the drugs [9,16,17], thus en-
hancing the antitumor effectiveness of the drugs.
The topic of US-medicated drug delivery has been
discussed in a number of excellent reviews [9,16,18-21].
The purpose of this article is to review the progress in
therapeutic benefit studies using UTMD to enhance the
delivery of chemotherapy drugs to solid tumors, as it is
more closely related to future clinical applications than
other in vivo studies using UTMD in the delivery of
model drugs to normal animal models.
Current UTMD technique for tumor drug delivery
The UTMD technique uses US to force dynamic behav-
iors of MBs to increase tumor uptake of chemotherapeu-
tic agents at targeted locations. The use of xenograft or
orthotopic tumor models in evaluating the therapeutic
benefits of UTMD has been reported in the literature.
The US transducer is placed extracorporeally and di-
rected toward deeply located tumor sites. High spatial
resolution can be achieved using focused US with a
beam-width on the order of millimeters. Coupling
between the transducer and the animal skin is achieved
through US gel or water. The therapeutic drugs can be
co-administrated with MBs through intravenous injec-
tion, taking advantage of the enhanced delivery effect
of UTMD, or carried by the MBs on their shell or core in
various different ways, taking advantage of both increased
delivery and increased local concentrations of thedelivered substance [11]. After bolus injection, MBs arrive
at the tumor site in approximately a few seconds, and their
lifetime is approximately 5 min [22]. For continuous injec-
tion, MBs can be effective for longer time. After MBs
reached the targeted tumor region, US is then focused on
the tumor in an effort to locally deliver the drug at the dis-
eased site as the interaction of the MBs and the tissue only
happens at the targeted location. To treat a larger area,
multiple spots are treated or the focus of the transducer is
scanned within the tumor. Although intravenous injection
was used most commonly, invasive direct intratumorally
injection of MBs was used by two groups [23,24]. Cur-
rently, US treatment is normally combined with magnetic
resonance imaging (MRI) or US imaging, assisting the
treatment with planning, monitoring, and evaluation strat-
egies [25,26].
Same as other therapeutic applications of US, UTMD
is a double-edged sword, in that on the one hand it is
requisite in promoting the transport of drugs into cells
and on the other hand it may damage tissues. The key
to achieve the desired bioeffects for efficient material
transfer is complimentary adjustments in US and MB
parameters. One of the most commonly used strategies
is to find a combination of parameters that induce bub-
ble activity sufficient to allow drug extravasation from
capillary walls without irreversibly damaging the endo-
thelial cells [27]. MB parameters include their sizes, shell
compositions, doses, and injection sites. The common
choice of the US center frequency is low megaHertz (e.g.,
1–5 MHz) to be close to the resonant frequencies of
MBs. The peak rarefactional pressures are normally low
(e.g., approximately 0.5 MPa) to induce cavitation while
minimizing the potential for tissue damage. Pulsed waves
are most commonly used with pulse durations on the
order of 10 ms. The pulse repetition frequency (PRF) is
normally close to the heart rate, e.g., 1–10 Hz, to allow
sufficient time between pulses for MBs to re-enter the
vasculature. In some studies, continuous waves were
used with the US on for several seconds followed by se-
veral seconds off, while the intensities were so low that
no thermal effect was induced [28,29]. Although success-
ful treatment of tumors was demonstrated in those stu-
dies, continuous waves are not optimal for drug delivery
application in consideration of the short lifetime of MBs
upon sonication.
In the last 10 years, extensive feasibility studies were
performed using UTMD in the delivery of model drugs
to normal animal models [30,31]. Most recently, a grow-
ing number of preclinical studies have been reported on
the efficacy of UTMD in treating tumors with chemo-
therapeutic drugs. Brain and liver cancers have been the
most broadly explored diseases for the application of
UTMD; there have also been publications on other can-
cers, such as eyelid, pancreas, and breast cancers. The
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quantified by high-performance liquid chromatography
or using a spectrophotometer, and the tumor volumes
were quantified based on direct caliber measurements or
images obtained with MRI, US, CT, or biophotonics.
These efficacy studies have shown promising results: in-
creased drug concentration in tumors and reduced
tumor sizes were achieved in tumors treated with
UTMD in combination with chemotherapeutic agents,
in comparison to tumors treated using conventional sys-
temic chemotherapy.
Preclinical applications of UTMD in oncology
UTMD therapy for brain cancer
Current methods of chemotherapeutic agent delivery
have limited success for patients with glioma tumors be-
cause of the existence of the blood–brain barrier (BBB)
in the brain. Although brain tumor capillaries may have
increased permeability, the BBB remains a formidable
obstacle in the treatment of brain malignancies. UTMD
has been established as a promising technology for non-
invasive, transient, reversible, and local BBB disruption
[32,33].
The first efficacy study using UTMD for chemotherapy
delivery to animals with glioma tumors was published by
Liu et al. [34]. The rat brain glioma model was devel-
oped by direct intracranial injection of gliomal tumor
cells. Following intravenous injection of MBs (SonoVue®,
Bracco Diagnostics, Milan, Italy), 1,3-bis-(2-chloroethyl)-
1-nitrosourea (BCNU), a common chemotherapeutic
agent for brain tumors, was intravenously injected. Then
the targeted tumor region was sonicated transcranially
using a MR-monitored focused US transducer with 0.4-
MHz frequency, 0.62-MPa pressure, 10-ms pulse length,
1-Hz PRF, and 30-s sonication time (Table 1). These pa-
rameters are within the range of most commonly used
parameters for BBB opening. After US treatment, it wasTable 1 Summary of UTMD in brain tumor therapy studies
Reference Animal
model
Chemo drug MB US

























Dox 5.67 mg/kg Definity® 0.01-0.02
ml/kg
1.7found that BCNU concentration increased by nearly two
times at the UTMD-treated brain compared with un-
treated control. The median survival time for the con-
trol, BCNU, and BCNU + UTMD were 28.5, 33
(p=0.023 relative to control), and 53 (p=0.0015 relative
to control) days, respectively. This study demonstrated
the feasibility of UTMD for increasing localized chemo-
therapeutic drug delivery with chemotherapeutic doses
in the tumor region to suppress tumor growth and pro-
long animal survival. It is unclear why the animal sur-
vival declined rapidly after 50 days. It is important to
investigate the systemic toxicity of the treatment and
biodistribution of the chemotherapeutic agent to dem-
onstrate conclusively the safety and efficacy of this
approach.
Recently, multifunctional MBs capable of BCNU load-
ing, BBB opening induction, and local BCNU release
were developed and used in UTMD-enhanced drug de-
livery to brain tumors [35]. The US treatment parame-
ters were similar to the above study (Table 1). However,
instead of single transcranial treatment, the study was
performed multiple times with a craniotomy. Treat-
ments were on two consecutive days, and each day, two
repeated treatments were performed. Encapsulation of
the BCNU in MBs (BCNU-MBs) prolonged BCNU's cir-
culatory half-life significantly and reduced the systemic
toxicity. The median survival for the untreated control,
BCNU, and BCNU-MBs + US was 29, 29.5, and 32.5
days, respectively. The maximum survival for the three
groups was 38, 43, and 59 days, respectively. The in-
crease in the maximum survival was significant compar-
ing the US-treated group and the control. However, it is
not clear from this paper whether the increase in median
survival is significant. This study demonstrated that the
use of MBs carrying chemotherapeutic agents in com-
bination with US exposure is a feasible approach to
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parameters used in this study had been optimized based
on studies using normal animal model, the median sur-
vival time of 32.5 days achieved with BCNU-MBs + US
was much lower than the 53 days reported in the above
study (Liu et al. [34]) using BCNU + MBs + US while
the median survival time of their control groups was
close (28.5 and 29 days, respectively). Future work is
needed to compare these two strategies to demonstrate
whether BCNU-loaded MBs can further improve the
therapeutic efficacy.
Doxorubicin (Dox) is another chemotherapeutic agent
with demonstrated antineoplastic efficacy and wide-
spread clinical use but cannot cross the intact BBB. The
first study that demonstrated the therapeutic benefit of
delivering Dox across the BBB using UTMD was pub-
lished by Treat et al. [36] (Table 1). Rats with implanted
brain glioma tumors were treated transcranially with
MRI-guided focused ultrasound. Sonication after bolus
injection of MBs (Definity®, Lantheus Medical Imaging,
North Billerica, MA, USA) was repeated every 5 min in
overlapping square pattern until the entire projected
area of the tumor on the MRI image had been exposed
to the acoustic focus. For each sonication, Dox hydro-
chloride encapsulated in long-circulating pegylated lipo-
somes was injected immediately after the administration
of MBs. Delayed tumor growth was demonstrated by the
increase of tumor doubling time constants from 2.3 days
for the untreated control to 3.7 days for UTMD + Dox.
The median survival times for the control, US only, Dox
only, and UTMD + Dox were 25, 25, 29, and 31 days, re-
spectively. The median survival time of the last group was
significantly higher than that of the control (p = 0.0007).
The demonstration of increased antitumor efficacy of
Dox by UTMD represents a major milestone in the de-
velopment of this technique for clinical application.
However, the increase in survival time is modest, suggesting
that future optimization is needed to further improve
the efficacy.Table 2 Summary of UTMD in liver tumor therapy studies
Reference Animal
model
Chemo drug MB U




























Dox 167 μg/rat Dox-loaded
polymer
MBs
- 1UTMD therapy of liver cancer
Hepatocellular carcinoma ranks as the third most com-
mon cause of death from cancer worldwide. Unfortu-
nately, liver cancer resists most chemotherapy drugs.
Chemotherapy drugs are effective in only a small pro-
portion of liver tumors, and the responses often are not
durable. UTMD has been proposed as a new strategy for
chemotherapy drug delivery to liver tumors.
Kang et al. [29] investigated the possibility of using
UTMD with docetaxel-loaded lipid MBs (Dox-MB) to in-
hibit the growth of liver tumors in an orthotpic animal
model by releasing the drug locally and enhancing its de-
livery to carcinoma tissues. Instead of using a focused
ultrasound transducer as used in most studies, a 0.3-MHz
non-focused US transducer was used for the treatment
with an intensity of 2 W/cm2. Tumors were exposed for
10 s followed by 10 s off, with a total treatment duration
of 6 min (Table 2). The treatments were performed on
three separate times on days 1, 4, and 7. It was found that
UTMD with Dox-MBs inhibited the growth of the liver tu-
mors by decreasing proliferation and promoting apoptosis.
Compared with the untreated control, the mean survival
time of the Dox-MBs + US group increased from 23.6 to
36.8 days (p < 0.01) and the extensive metastasis rate de-
creased from 100% to 0% (p < 0.01). The efficacy of
UTMD in this study can be further improved, as the ultra-
sound frequency was much lower than the resonant fre-
quency of the MBs. Moreover, as mentioned before, the
strategy of turning ultrasound on for 10 s followed by 10 s
off was not optimized in considering MB dynamics.
One of the obstacles for clinical use of UTMD is that
MBs have limited loading capacity of chemotherapy
drugs because they have a thin shell (few nanometers)
and gas core. Instead of working to increase the loading
of the MBs, Li et al. [28] used a powerful antitumor
drug: 10-hydroxycamptothecin (HCPT). The required
dose of HCPT for cancer therapy is over 20 times lower
than that of paclitaxel or doxorubicin. Therefore, a
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injected intravenously, followed by sonication. Focused
US parameters were the same as the above study with
the exception that the frequency was 1 MHz instead of
0.3 MHz and treatment was performed once a day for
seven consecutive days (Table 2). The group treated with
HCPT-MBs + US exhibited a fivefold higher HCPT con-
centration in tumor tissues at 4 h post-administration of
HCPT and a 1.5-fold higher tumor inhibition rate com-
pared to that of HCPT-MBs alone at the second day
after the last treatment. The results obtained in this
study indicate that HCPT-MBs may be capable of over-
coming the current limitation of drug payload of MBs
depending on the agent used. Long-term survival studies
need to be performed to determine whether the tumor
inhibition effect can be sustained.
Doxorubicin-loaded polymer MB is another platform
proposed for UTMD. Using a rat liver cancer model,
Cochran et al. [37] examined the biodistribution and de-
livery of polymer MB loaded with 14C-labeled doxorubi-
cin. The tumor was continuously insonated using a
diagnostic ultrasound scanner (Philips HDI-500, Philips,
Bothell, WA, USA) with a linear 12–5-MHz transducer.
The scanner was operated in Doppler mode with a
mechanical index of 0.4–0.45 and a PRF of 1 kHz
(Table 2). Compared to the group treated by free doxo-
rubicin, animals treated with Dox-MBs + US had signifi-
cantly lower plasma Dox concentration, lower drug
levels in the myocardium, higher drug levels in tumors,
and less tumor growth. Autoradiography of tumor sec-
tions showed that the majority of Dox was restricted to
the periphery of the tumor. It is hypothesized by the au-
thors that after the drug-loaded MBs were fragmented
by US to nanoparticles at the tumor site, they are cap-
able of escaping the tumor vasculature, accumulating
within the tumor, and slowly releasing the drug. This
































Taxol 0.22 mg/mouse Definity® 30 μL/moupromising platform for chemotherapy drug delivery. It
also demonstrated that a commercial ultrasound scanner
can be successfully used for drug delivery with UTMD,
which may lead to easier clinical translation of this tech-
nique. However, future work is needed to develop a
more sophisticated ultrasound regimen to enhance the
penetration of drugs into tumors.
UTMD therapy of other cancers
Besides brain and liver cancers, UTMD has also been
explored in the treatment of other cancers. Examples of
its application in eyelid, pancreas, and breast cancers are
described below.
Melanomas of the eye can involve various ocular
structures, including the eyelid, conjunctiva, and uvea,
but their treatment is difficult. UTMD has been used in
the treatment of mice xenograft eyelid tumors [23]. An
antitumor drug, bleomycin, was mixed with Optison®
MBs (Amersham Health, Princeton, NJ, USA) and then
injected directly into the center of the tumor using a syr-
inge. Immediately after the injection, a Sonitron 2000TM
probe (Rich Mar Inc., Inola, OK, USA), a non-focused
transducer designed for sonoporation, was placed
directly on the tumor surface for US sonication with the
following parameters: 1-MHz frequency, 2-W/cm2
power density, 50% duty cycle, and 240-s duration
(Table 3). The antitumor effect of bleomycin was ob-
served when the treatment was used in conjunction with
UTMD. Immunostaining revealed that a high rate of
bleomycin was introduced into the tumor cells. No ab-
normalities such as inflammation or degeneration in any
tissues, such as brain, lung, liver, or heart, were observed
on day 14. This study demonstrated that UTMD is a
promising technology; however, the direct intratumoral
injection is an invasive approach, and whether it can in-
crease drug delivery when compared with intravenous
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of the most difficult cancers to treat, with a 5-year rela-
tive survival of 6%. In a study by Tinkov et al. [38], PDA
cells were orthotopically grown in the pancreas tails of
nu/nu mice. Following the intravenous injection of Dox-
loaded MBs, a diagnostic ultrasound system, Sonos 5500
(Philips, Eindhoven, The Netherlands), operating in
ultraharmonic mode was used for the sonication. A
burst of four frames of US every four cardiac cycles was
delivered during a constant rate infusion of MBs for 20
min (Table 3). A 12-fold increase in tissue concentration
was achieved in targeted tumors with a threefold de-
crease in tumor growth compared to the contralateral
control tumor.
Breast cancer ranks second as a cause of cancer death
in women (after lung cancer). Chemotherapy may be
used before surgery removal to shrink the cancer or after
the surgery to get rid of any cancer cells that may be left
behind after surgery or to reduce the risk of the cancer
coming back. Sorace et al. [39], using a subcutaneous
breast cancer animal model, explored the effect of mech-
anical index (MI) on the in vivo tumor growth and ne-
crosis (Table 3). MI is defined by the peak negative
pressure of the ultrasound wave divided by the square
root of its center frequency. MB-mediated focused US
therapy using a MI value of 0.5 resulted in the highest
impediment in tumor growth over the 3-week treatment
period and also the highest degree of necrosis per tumor
volume, followed by therapy using MI of 1.0, 0.1, and 2.
A MI of 2.0 exhibited very little tumor necrosis, 17 times
less than that with a MI of 0.5. Excessively high MI
values have been shown to cause bursting of capillaries
[40], which in turn could decrease drug delivery to the
tumor cells. Conversely, when a low MI is used, there is
thought to be little MB cavitation, creating no enhanced
drug delivery. All the previous mentioned studies were
performed with one fixed group of parameters. This is
the first study that explored the effect of acoustic param-
eters on the efficacy of UTMD cancer treatment.
Current limitations and future perspectives
The preclinical data appear promising to date for
UTMD-mediated delivery of chemotherapy agents into
tumors. However, there are still a number of concerns
and obstacles that have slowed its progress toward clin-
ical translation.
As pointed out earlier, although MBs are relatively
large agents, the amount of drug that can be attached to
the bubble surface or incorporated into the internal lipid
layer is limited because of its thin shell and gas core.
Using an antitumor drug with powerful activity is a
promising approach; however, this drug may not be ap-
plicable to all types of tumors. The loading capacity can
be increased if multilayers or additional oil layers areused. However, such MBs may significantly change their
size and acoustic behavior. Insufficient loading capacities
can be circumvented by co-administration of the thera-
peutic substance with MBs. With this method, no limita-
tions exist for the amount of bioactive drugs. However,
this strategy can only take advantage of transiently in-
creased local permeability and not of increased local
concentrations of the delivered drugs. In the future, new
drug-specific MBs that can load optimal amounts of the
drug without losing their acoustic behavior need to be
developed.
Although the circulation time of MBs has increased in
the past several years by improving their manufacturing
techniques, this remains to be a concern for UTMD
drug delivery. MBs are typically administered into a per-
ipheral vein, so only a small amount of agent will pass
through a tumor in a given circulatory cycle. Multiple
circulations are necessary to allow destruction of enough
agents to increase local concentration significantly.
Therefore, the circulation time needs to be sufficient
enough to allow higher amount of drug to be delivered
to the targeted region. MB circulation times increase sig-
nificantly with MB size, which is expected given the rela-
tionship of bubble dissolution to their diameter [41].
Using monodispersed MBs with larger sizes may im-
prove the efficacy of UTMD treatment [42] not only be-
cause larger bubbles may generate larger mechanical
effect on the tissue but also because they have longer
circulation times.
Several different US systems have been used for
UTMD, including focused ultrasound transducers, non-
focused ultrasound transducers, and diagnostic US sys-
tems. Focused transducers have the advantage of high
spatial resolution for tumor treatment as the beam-
width can be focused to a few millimeters; however, to
treat larger tumor areas, scanning will be needed, which
requires longer treatment times. The non-focused trans-
ducers have the advantage of covering larger tumor area;
however, the downside is the potential to affect non-
tumor tissue along the acoustic path. The ability to use
diagnostic US systems for therapeutic application is at-
tractive, as it will simplify the clinical translation of the
UTMD technique. However, the frequency of the im-
aging transducers and the pulse sequences are not ne-
cessarily optimized for drug delivery. Optimal US
modalities have to be designed to improve its efficiency
in MB activation.
A major challenge in the future clinical application of
UTMD is the control over the procedure to ensure both
safe and effective treatment. Extensive studies have dem-
onstrated that cavitation is the main mechanism for
UTMD-enhanced drug delivery [6,43]. Cavitation detec-
tion techniques have been developed to monitor the
acoustic emissions from the oscillating MBs during
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been shown to be correlated with the extravasation of
delivered agents [25]. The emissions have also been used
as the basis for a feedback control algorithm to actively
control US exposures to ensure safe treatment [47]. How-
ever, these studies were performed using non-tumor-bearing
animals, while no investigation of cavitation activity
was reported in all the previously mentioned studies. In
the future, cavitation monitoring techniques should be
incorporated to assist treatment outcome prediction
and ensure safe treatments.
For future clinical translation, animal models that bet-
ter recapitulate human tumors are needed. For example,
it is known that xenograft and orthotropic pancreatic
cancer models lack the prominent stromal matrix separ-
ating blood vessels from tumor cells, observed in human
tumors. The stromal matrix has been demonstrated to
be an important barrier to drug delivery in pancreatic
cancer [48]. Thus, the success achieved in drug delivery
using xenograft and orthotropic pancreatic cancer
models may not be directly translatable to clinical appli-
cation. Meanwhile, larger animal models are needed to
scale up the treatment. Most recently, studies of
UTMD-enhanced model drug delivery to normal mon-
key brain were reported [49,50]. Although no thera-
peutic agents were used, these preliminary results
demonstrate the feasibility of performing the treatment
on large animals more similar in scale to humans. Future
successful preclinical applications of UTMD in realistic
tumor models that are similar to human tumors should
pave the way for clinical applications.
Last but not least, further evaluation of the safety of
UTMD-mediated chemotherapy delivery is needed.
There appears to be a consensus that a MI value of 0.4
represents the threshold for MB-induced bioeffects.
Bioeffects, such as microvascular leakage, petechiae,
cardiomyocyte death, inflammatory cell infiltration, and
premature ventricular contractions, have been observed
in animals in vivo [51]. For diagnostic applications, these
bioeffects raise safety concerns; however, for therapeutic
applications, MBs are used to induce bioeffects for
therapeutic benefits, for example, to enhance vascular
permeability of chemotherapy drugs. Assessment of
safety for therapeutic applications must take a different
form than for diagnostic applications [52]. Currently, the
safety of UTMD in cancer therapy is mainly evaluated
by animal survival. The systemic toxicity of the treat-
ment needs to be investigated to demonstrate conclu-
sively the safety of this technique.
Summary
The use of UTMD as a tool for drug delivery has an enor-
mous clinical potential in oncology. Whereas free drugs
often possess harmful side effects, their encapsulation inMBs and subsequent local release and uptake in the target
tissue by US triggering may help to improve the thera-
peutic outcome. A growing number of preclinical studies
have successfully demonstrated the therapeutic benefits of
UTMD in the delivery of chemotherapeutic drugs to
various malignant tumors, such as brain, liver, eyelid, pan-
creas, and breast tumors. However, future improvements
are needed in (1) the manufacture of MBs with longer
circulation times and higher loading capacities without
significantly altering their acoustic behavior, (2) the
optimization of US modalities to improve their efficiency
in MB activation, (3) the incorporation of cavitation moni-
toring techniques to assist in treatment monitoring, and
(4) the evaluation of therapeutic benefits in realistic tumor
models that are similar to human tumors. Nevertheless,
the successful results already obtained in preclinical appli-
cations give great hope to future clinical translation of
UTMD in cancer treatment.
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